For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?
Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.
Phase II publication
Jänne et al., PMID 35658005
Community PollStarted
What is your preferred second line therapy in KRAS-G12c mutated NSCLC with CNS metastases?
91 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Yale School of Medicine
Answered on
Sotorasib is currently my drug of choice for now, since it is FDA approved. The KRYSTAL-1 results for adagrasib were presented at ASCO 2022, and the efficacy is very similar vs sotorasib, 43% vs 37% ORR, 80% DCR for both, 6.5 vs 6.8 mo mPFS, and 12.6 vs 12.5 mo mOS. Adagrasib does seem to have more ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on · Updated on
The incidence of CNS metastases in KRASG12Cmutated NSCLC is approximately 27 to 42% at diagnosis and is associated with a poor prognosis. The current standard of care for this group of patients is docetaxel plus ramucirumab which is associated with a median PFS of approximately 3 to 5 months. (Furuy...
Join for free or sign in to see the full answer